PDF(Pubmed)
Abstract：
Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered \"unmodifiable\". The present paper is a viewpoint aimed at presenting the incremental metabolic and cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their prescription by physicians and their assumption by patients, which need to be worked out for a more diffuse and appropriate drug utilization.
摘要：
创新的脂质调节剂是改善对动脉粥样硬化血脂异常的控制并降低不耐受或对综合护理标准（他汀类药物加依泽替米贝）不完全反应的患者与脂质相关的残余心血管风险的宝贵资源。此外，一些即将到来的化合物会有效影响到目前为止被认为是“不可改变的”的脂质目标。本文是一个观点，旨在介绍新兴的脂质调节剂和现实生活中的屏障的增量代谢和心血管益处，阻碍了医生的处方和病人的假设，需要制定更分散和适当的药物利用。
